---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105002"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:50:01.860552+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dianthus Q2 net loss $31.6M ($0.88/sh); cash $309.1M; gMG Ph2 data due Sept

## Summary
- Cash, cash equivalents and investments $309.1M as of June 30, 2025; runway into 2H 2027.
- Net loss $31.6M ($0.88 basic/diluted EPS) vs $17.6M ($0.51) in Q2 2024.
- R&D expenses $26.3M (incl. $2.5M stock-based) vs $18.1M; increase driven by Phase 2/3 costs.
- Top-line Phase 2 MaGic trial results for claseprubart in gMG anticipated September 2025.
- Phase 3 CAPTIVATE CIDP trial on track; interim responder analysis expected 2H 2026.

## SEC filing metadata
- accession: 0000950170-25-105002
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017025105002/0000950170-25-105002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017025105002/dnth-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105002
- JSON: https://secwatch.observer/filing/0000950170-25-105002.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.